Big Pharma Split Corp Class A (PRM) — Cash Flow Quality Index
Big Pharma Split Corp Class A (PRM) has a Cash Flow Quality Index of -0.19x as of December 2025. Operating cash flow of CA$-910.98K is below net income of CA$4.89 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore PRM cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Big Pharma Split Corp Class A Cash Flow Quality Index (2018–2025)
Historical Cash Flow Quality Index for Big Pharma Split Corp Class A across 5 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see Big Pharma Split Corp Class A cash conversion from operations.
Annual Cash Flow Quality Index for Big Pharma Split Corp Class A (2018–2025)
Year-by-year earnings quality comparison for Big Pharma Split Corp Class A.
| Year | Quality Index | Operating CF (CAD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | -0.24x | CA$-1.06 Million | CA$4.40 Million | ▼ -150.8% |
| 2022 | 0.47x | CA$1.13 Million | CA$2.39 Million | ▲ +122.1% |
| 2021 | -2.14x | CA$-9.00 Million | CA$4.21 Million | ▼ -163.6% |
| 2019 | 3.36x | CA$8.68 Million | CA$2.58 Million | ▲ +457.3% |
| 2018 | 0.60x | CA$1.27 Million | CA$2.10 Million | — |